Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Mercadolibre Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.67 (market cap $39.89B), while Mercadolibre Inc trades at $1,873.96 (market cap $93.90B). The key difference: Mercadolibre Inc is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Mercadolibre Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MELI | |
|---|---|---|
Market Cap | $39.89B | $93.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $2.51K |
52-Week Low | $278.09 | $1.55K |
Enterprise Value | $38.15B | $100.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MercadoLibre (MELI) trades at $1,852.22, up 2.46% today, with a bullish technical signal from moving averages and strong analyst support (23 buy, 0 sell). Revenue grew to $28.89B in 2025, though net income margin compressed to 6.04% amid heavy investment. Recent news highlights investigations by law firms and debates over profitability versus growth, while cash flow from operations surged to $12.12B.
Outlook remains positive given dominant Latin American e-commerce position and 49% revenue growth, but risks include margin pressure from capex, legal scrutiny, and high valuation multiples. The consensus price target of $2,230 implies ~20% upside, contingent on execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
